Conference Coverage
about 1 month ago
In a Matter of Months, MMR Vaccine Confidence Drops Significantlyabout 1 month ago
Clinical Takeaways From ViiV’s PASO DOBLE and CLARITY StudiesLatest Content
Dec 10, 2025 | News
FDA Plans to Review Already Approved RSV Immunizations
NYU’s Vaccine Center: A Short History With Significant Contributions
Dec 10, 2025
‘Complicating the Decision-Making’ for the Universal Birth Dose of the Hepatitis B Vaccine
Dec 10, 2025
FDA Grants First Approval Under Priority Voucher Program, Fast-Tracking Antibiotic to Strengthen US Drug Supply Chain
Dec 09, 2025
House Lawmakers Probe FDA Over COVID-19 Vaccine Death Claims and Proposed Vaccine Regulation Changes
Dec 09, 2025
Advertisement
Shorts
0:39
Challenges of Acquiring Phage Therapy
a month ago
by
Ashlan Kunz Coyne, PharmD, MPH(+1 more)
0:48
Building Parents' Trust About Childhood Vaccines
a month ago
by
Ruth Lynfield, MD(+1 more)
0:14
A Monoclonal Antibody as a COVID-19 Alternative
a month ago
by
Robert Allen, PhD(+1 more)
0:36
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
2 months ago
by
Barry Kreiswirth, PhD(+1 more)
0:36
The Center for Discovery and Innovation’s Commitment to Fungal Diagnostics and Treatment
2 months ago
by
David Perlin, PhD(+1 more)
0:41
Kevin Ault, MD on ACIP Shared Decision-Making, Informed Consent, and Vaccine Policy
3 months ago
by
Kevin Ault, MD(+1 more)
0:52
Adoption of Rapid Diagnostic Tools, Susceptibility Testing for Gram-Negative Infections
3 months ago
by
Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; and Ryan P. McNamara, PhD(+1 more)
0:26
Why Intestinal Antibodies Are Key to Beating Norovirus Infection
3 months ago
by
Sean N Tucker, PhD(+1 more)
0:22
Examining Chronic Chikungunya and Potential Clues to Rheumatologic Symptoms
3 months ago
by
Daniela Weiskopf, PhD(+1 more)
0:28
Clinical Considerations for Using Newer Antibiotics for Gram-Negative Infections
3 months ago
by
Ryan K. Shields, PharmD, MS(+1 more)
Contagion: Summer 2025 Issue
View our interactive Summer 2025 issue, featuring articles on biosurveillance, aging in HIV, the NARROWS Framework for stewardship, and much more!
A Deep Dive: Understanding the Neurological Toll of Long COVID
Ravindra Ganesh, MD, MBBS, FACP, Dip ABOM, Svetlana Blitshteyn, MD, FAAN, and Monica Verduzco-Gutierrez, MD, discuss Long COVID's prevalence—noting that 1 in 5 Americans and 1 in 10 patients post-COVID may be affected.
Contribute to Contagion's Digital Book!
Contagion® is always looking for new contributors to the various sections of our book. Click to learn more about submitting.
Beyond the Virus: Long COVID’s Neurological Toll
There is increasing concern of Long COVID’s impact on the brain of patients previously infected with the virus. Featuring commentary from Jennifer Frontera, MD; Leigh Elkins Charvet, PhD; Neil Busis, MD; Alba Azola, MD; and Kristine Erlandson, MD.
COVID-19 Therapeutic Management and Prevention
Tina Tan, MD; Scott Roberts, MD; James Wilson, DO, FACP, FAWM, CTropMed; and Michael Curulewski, PharmD, BCPS, BCIDP, BCGP, discuss FDA-approved COVID-19 therapies, off-label treatments, and preventive modalities.
Podcasts
Videos
Contagion Digital Edition
The NARROWS framework, developed within the IDSA Core Antimicrobial Stewardship Curriculum, provides a structured, behaviorally informed approach to communication that helps stewardship teams address the social, emotional, and cultural factors influencing prescribing decisions in order to optimize antimicrobial use and combat resistance.
Stenotrophomonas maltophilia is an opportunistic, multidrug-resistant pathogen that poses significant treatment challenges due to its complex resistance mechanisms, limited therapeutic options, and high mortality rates among vulnerable patients.
This review highlights how people living with HIV are living longer due to antiretroviral therapy but face unique age-related health challenges, including cardiovascular disease, metabolic syndrome, renal dysfunction, neurocognitive decline, immunosenescence, bone loss, and frailty, requiring tailored screening and management strategies.
Biosurveillance is an essential early warning system for detecting and responding to infectious disease threats, helping to prevent localized cases from becoming widespread outbreaks or pandemics. Despite its proven value during crises such as COVID-19, biosurveillance programs often suffer from inconsistent funding and support, underscoring the urgent need for sustained investment and integration into public health infrastructure.
Clinical trial and real-world data, including the PROVE study, support its role as an effective and carbapenem-sparing therapy for serious infections, though outcomes vary depending on pathogen and infection type.
Doxycycline postexposure prophylaxis is associated with emerging tetracycline resistance in Neisseria gonorrhoeae and commensal organisms, highlighting the need for cautious, targeted use.
A recent literature review describes the current state of artificial intelligence tools for guiding antimicrobial therapy. Are you ready for change?
A preventable crisis, measles, makes a dangerous comeback.
De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.
Continuing Medical Education
All News
Advertisement
Advertisement
A large meta-analysis indicates opioid exposure may disrupt immunity and gut microbiota, increasing CDI vulnerability and potentially worsening clinical outcomes.
Angelica Cifuentes Kottkamp, MD, discusses how its location, breadth of experience, and opportunities afford clinicians the ability to see and treat a wide berth of diseases and infections.
Most clinical isolates identified as triazole-resistant Aspergillus niger by traditional clinical laboratory methods were revealed by DNA sequencing to be A tubingensis.
Population study corroborates 2019 FDA alert based on case reports of acute respiratory failure with TMP-SMX in healthy adolescents and young adults.
This week, read our coverage on the CDC ACIP meetings on the hepatitis B virus (HBV) vaccine, modeling data on the potential consequences of HBV infections, liver cancer, and mortality when delaying the birth dose to 2 months, our latest podcast, and more.
Lacking any safety data showing potential serious adverse effects, the committee decided to move forward with the recommendation “that the initial dose administered no earlier than 2 months of age.”
Due to repetitive and confusing language, the committee decided to amend the votes for clarity and will vote on 3 new recommendations on Friday.
Anticipating possible constraints on the approval of COVID-19 vaccines and their removal from the CDC pediatric vaccine schedule, a medical ethicist and legal scholar consider off-label vaccination.
A public health and farmworker coalition says agricultural spraying of medically important antibiotics and antifungals contributes to environmental resistance and warrants EPA cancellation.
New Centers for Disease Control and Prevention (CDC) data show rising early-season influenza activity, moderate 2024–2025 vaccine effectiveness, and updated 2025–2026 recommendations that include trivalent, thimerosal-free single-dose formulations and expanded access to FluMist.
Advertisement
A new analysis shows thousands of children could contract hepatitis B, leading to further complications and deaths, if the vaccine schedule recommendations are changed to later in a child's life.
Improving public awareness of appropriate antibiotic use could complement antibiotic stewardship programs worldwide.
WHO and UNAIDS warn of service disruptions, widening inequities, and mounting drug-resistance threats, while highlighting innovations and commitments needed to end AIDS as a public health threat.
In our latest podcast, Elizabeth Marlowe, PhD, D(ABMM), discusses the findings of Quest Diagnostics' large US HIV testing study, which showed a significant decline in HIV drug resistance across major antiretroviral classes, reflecting the impact of modern high-barrier therapies and improved viral suppression.
The New Jersey company recently announced the partnership that includes federal funding to create new treatments from a novel class of fungerps.
Advertisement
Advertisement
Trending on Contagion Live
1
FDA Grants First Approval Under Priority Voucher Program, Fast-Tracking Antibiotic to Strengthen US Drug Supply Chain
2
House Lawmakers Probe FDA Over COVID-19 Vaccine Death Claims and Proposed Vaccine Regulation Changes
3
‘Complicating the Decision-Making’ for the Universal Birth Dose of the Hepatitis B Vaccine
4
Opioid Use Linked to Nearly Double the Risk of C difficile Infection
5
